{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:20:36Z","timestamp":1782782436872,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GTN1176538"],"award-info":[{"award-number":["GTN1176538"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002066","name":"GlaxoSmithKline foundation","doi-asserted-by":"publisher","award":["ISS 209462"],"award-info":[{"award-number":["ISS 209462"]}],"id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Serono"},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study examines the association of standard-of-care systemic lupus erythematosus (SLE) medications with key outcomes such as low disease activity attainment, flares, damage accrual, and steroid-sparing, for which there is current paucity of data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The Asia Pacific Lupus Collaboration (APLC) prospectively collects data across numerous sites regarding demographic and disease characteristics, medication use, and lupus outcomes. Using propensity score methods and panel logistic regression models, we determined the association between lupus medications and outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 1707 patients followed over 12,689 visits for a median of 2.19 years, 1332 (78.03%) patients achieved the Lupus Low Disease Activity State (LLDAS), 976 (57.18%) experienced flares, and on most visits patients were taking an anti-malarial (69.86%) or immunosuppressive drug (76.37%). Prednisolone, hydroxychloroquine and azathioprine were utilised with similar frequency across all organ domains; methotrexate for musculoskeletal activity. There were differences in medication utilisation between countries, with hydroxychloroquine less frequently, and calcineurin inhibitors more frequently, used in Japan. More patients taking leflunomide, methotrexate, chloroquine\/hydroxychloroquine, azathioprine, and mycophenolate mofetil\/mycophenolic acid were taking\u2009\u2264\u20097.5 mg\/day of prednisolone (compared to\u2009&gt;\u20097.5 mg\/day) suggesting a steroid-sparing effect. Patients taking tacrolimus were more likely (Odds Ratio [95% Confidence Interval] 13.58 [2.23\u201382.78], <jats:italic>p<\/jats:italic>\u2009=\u20090.005) to attain LLDAS. Patients taking azathioprine (OR 0.67 [0.53\u20130.86], <jats:italic>p<\/jats:italic>\u2009=\u20090.001) and methotrexate (OR 0.68 [0.47\u20130.98], <jats:italic>p<\/jats:italic>\u2009=\u20090.038) were less likely to attain LLDAS. Patients taking mycophenolate mofetil were less likely to experience a flare (OR 0.79 [0.64\u20130.97], <jats:italic>p<\/jats:italic>\u2009=\u20090.025). None of the drugs was associated with a reduction in damage accrual.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study suggests a steroid-sparing benefit for most commonly used standard of care immunosuppressants used in SLE treatment, some of which were associated with an increased likelihood of attaining LLDAS, or reduced incidence of flares. It also highlights the unmet need for effective treatments in lupus.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42358-024-00366-y","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T10:02:26Z","timestamp":1715162546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study"],"prefix":"10.1186","volume":"64","author":[{"given":"Ricardo Az\u00eado","family":"de Luca Montes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molla","family":"Huq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Oon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Calderone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rangi","family":"Kandane-Rathnayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worawit","family":"Louthrenoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shue-Fen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeong-Jian","family":"Jan Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Golder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Lateef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra V.","family":"Navarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laniyati","family":"Hamijoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sargunan","family":"Sockalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelynn","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Goldblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chak Sing","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacai","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Hoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan S.","family":"Karyekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric F.","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6585-5611","authenticated-orcid":false,"given":"Mandana","family":"Nikpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"366_CR1","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1177\/0961203310375832","volume":"19","author":"MY Mok","year":"2010","unstructured":"Mok MY, Li WL. Do Asian patients have worse lupus? Lupus. 2010;19:1384\u201390.","journal-title":"Lupus"},{"key":"366_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/0021-9681(55)90018-7","volume":"1","author":"M Merrell","year":"1955","unstructured":"Merrell M, Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis. 1955;1:12\u201332.","journal-title":"J Chronic Dis"},{"key":"366_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","volume":"82","author":"R Cervera","year":"2003","unstructured":"Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82:299\u2013308.","journal-title":"Medicine (Baltimore)"},{"key":"366_CR4","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2665-9913(19)30105-5","volume":"2","author":"D Apostolopoulos","year":"2020","unstructured":"Apostolopoulos D, Kandane-Rathnayake R, Louthrenoo W, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study. Lancet Rheumatol. 2020;2:e24\u2013e30.","journal-title":"Lancet Rheumatol"},{"key":"366_CR5","doi-asserted-by":"publisher","first-page":"e000066","DOI":"10.1136\/lupus-2014-000066","volume":"2","author":"S Al Sawah","year":"2015","unstructured":"Al Sawah S, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus \u2013 the Hopkins Lupus Cohort. Lupus Sci Med. 2015;2:e000066.","journal-title":"Lupus Sci Med"},{"key":"366_CR6","doi-asserted-by":"crossref","unstructured":"The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324:150\u201354.","DOI":"10.1056\/NEJM199101173240303"},{"key":"366_CR7","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/art.24068","volume":"15","author":"PR Fortin","year":"2008","unstructured":"Fortin PR, Abrahamowicz M, Ferland D, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008;15:1796\u2013804.","journal-title":"Arthritis Rheum"},{"key":"366_CR8","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75:1615\u201321.","journal-title":"Ann Rheum Dis"},{"key":"366_CR9","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","volume":"1","author":"V Golder","year":"2019","unstructured":"Golder V, Kandane-Rathnayake R, Huq M, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatol. 2019;1:e95\u2013e102.","journal-title":"Lancet Rheumatol"},{"key":"366_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/1756-185X.13431","volume":"22","author":"R Kandane-Rathnayake","year":"2019","unstructured":"Kandane-Rathnayake R, Golder V, Louthrenoo W, et al. Development of the Asia Pacific Lupus Collaboration cohort. Int J Rheum Dis. 2019;22:425\u201333.","journal-title":"Int J Rheum Dis"},{"key":"366_CR11","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.","journal-title":"Arthritis Rheum"},{"key":"366_CR12","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alacron GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677\u201386.","journal-title":"Arthritis Rheum"},{"key":"366_CR13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/art.1780390303","volume":"39","author":"D Gladman","year":"1996","unstructured":"Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363\u201369.","journal-title":"Arthritis Rheum"},{"key":"366_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/0961203310385163","volume":"20","author":"Z Touma","year":"2011","unstructured":"Touma Z, Urowitz MB, Ibanez D, Gladman DD. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus. 2011;20:67\u201370.","journal-title":"Lupus"},{"key":"366_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00004","volume":"142","author":"JP Buyon","year":"2005","unstructured":"Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:953\u201362.","journal-title":"Ann Intern Med"},{"key":"366_CR16","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/art.24698","volume":"61","author":"RA Furie","year":"2009","unstructured":"Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61:1143\u201351.","journal-title":"Arthritis Rheum"},{"key":"366_CR17","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1136\/ard.2006.068676","volume":"66","author":"GS Alarc\u00f3n","year":"2007","unstructured":"Alarc\u00f3n GS, McGwin Jr. G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66:1168\u201372.","journal-title":"Ann Rheum Dis"},{"key":"366_CR18","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1177\/0961203312450084","volume":"21","author":"E Cairoli","year":"2012","unstructured":"Cairoli E, Rebella M, Danese N, Garra V, Borba EF. Hydroxychloroquine reduces lowdensity lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect. Lupus. 2012;21:1178\u201382.","journal-title":"Lupus"},{"key":"366_CR19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1055\/s-0037-1613033","volume":"87","author":"RG Espinola","year":"2002","unstructured":"Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost. 2002;87:518\u201322.","journal-title":"Thromb Haemost"},{"key":"366_CR20","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1093\/rheumatology\/kez562","volume":"59","author":"N Mena-V\u00e1zquez","year":"2020","unstructured":"Mena-V\u00e1zquez N, Fern\u00e1ndez-Nebro A, Pego-Reigosa JM, et al. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. Rheumatology (Oxford). 2020;59:2043\u201351.","journal-title":"Rheumatology (Oxford)"},{"key":"366_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1177\/0961203314567753","volume":"24","author":"GJ Pons-Estel","year":"2015","unstructured":"Pons-Estel GJ, Catoggio LJ, Cardiel MH, et al. Lupus in Latin-American patients: lessons from the GLADEL cohort. Lupus. 2015;24:536\u201345.","journal-title":"Lupus"},{"key":"366_CR22","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3899\/jrheum.111569","volume":"39","author":"M Kishimoto","year":"2012","unstructured":"Kishimoto M, Deshpande G, Yokogawa N, Buyon JP, Okada M. Use of Hydroxychloroquine in Japan. J Rheumatol. 2012;39:1296.","journal-title":"J Rheumatol"},{"key":"366_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3109\/s10165-012-0656-3","volume":"23","author":"N Yokogawa","year":"2013","unstructured":"Yokogawa N, Tanikawa A, Amagai M, et al. Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). Mod Rheumatol. 2013;23:318\u201322.","journal-title":"Mod Rheumatol"},{"key":"366_CR24","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","volume":"365","author":"MA Dooley","year":"2011","unstructured":"Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365:1886\u201395.","journal-title":"N Engl J Med"},{"key":"366_CR25","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","volume":"76","author":"J Ordi-Ros","year":"2017","unstructured":"Ordi-Ros J, S\u00e1ez-Comet L, P\u00e9rez-Consea M, et al. Enteric-coated mycphenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis. 2017;76:1575\u201382.","journal-title":"Ann Rheum Dis"},{"key":"366_CR26","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/annrheumdis-2017-212504","volume":"77","author":"EF Morand","year":"2018","unstructured":"Morand EF, Trasieva T, Berglind A, Illei G, Tummala R. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab. Ann Rheum Dis. 2018;77:706\u201313.","journal-title":"Ann Rheum Dis"},{"key":"366_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/annrheumdis-2018-214427","volume":"78","author":"S Oon","year":"2019","unstructured":"Oon S, Huq M, Golder V, Ong PX, Morand E, Nikpour M. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Ann Rheum Dis. 2019;78:629\u201333.","journal-title":"Ann Rheum Dis"},{"key":"366_CR28","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/rheumatology\/keaa029","volume":"59","author":"EF Morand","year":"2020","unstructured":"Morand EF, Isenberg DA, Wallace DJ, et al. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology (Oxford). 2020;59:930\u201338.","journal-title":"Rheumatology (Oxford)"},{"key":"366_CR29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392:222\u201331.","journal-title":"Lancet"},{"key":"366_CR30","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1093\/rheumatology\/keu148","volume":"53","author":"I Ruiz-Arruza","year":"2014","unstructured":"Ruiz-Arruza I. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2014;53:1470\u201376.","journal-title":"Rheumatology (Oxford)"},{"key":"366_CR31","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","volume":"74","author":"IN Bruce","year":"2015","unstructured":"Bruce IN, O\u2019Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals Rheum Dis. 2015;74:1706\u201313.","journal-title":"Annals Rheum Dis"},{"key":"366_CR32","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/art.21039","volume":"52","author":"B Fessler","year":"2005","unstructured":"Fessler B, Alarc\u00f3n GS, McGwin Jr G, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52:1473\u201380.","journal-title":"Arthritis Rheum"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-024-00366-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-024-00366-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-024-00366-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T04:08:04Z","timestamp":1721794084000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-024-00366-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["366"],"URL":"https:\/\/doi.org\/10.1186\/s42358-024-00366-y","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]},"assertion":[{"value":"22 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human research ethics approval for storage of the central dataset and analyses of the pooled data, was obtained from the Monash University Human Research Ethics Committee (MUHREC Project ID 18778), and all research subjects signed the informed consent form prior to commencement of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors R.M., M.H., E.M., and M.N. have received grant support or consulting fees from pharmaceutical sponsors. Author C.K. is an employee of Janssen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}